Elevated spondin-2 expression correlates with progression and prognosis in gastric cancer
Metrics: PDF 1621 views | HTML 1871 views | ?
Chuan Jin1,*, Jin-Rong Lin1,*, Lei Ma1, Ye Song1, Yan-Xia Shi1, Peng Jiang1, Ye Dong1, Xiao-Shan Li1
1Department of Medical Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, 510095, Guangdong, China
*These authors have contributed equally to this work
Xiao-Shan Li, email: [email protected]
Keywords: spondin-2, gastric cancer, aggressiveness, prognosis
Abbreviations: MMP-9, matrix metallopeptidase 9; UICC, Union International Cancer Control; IHC, immunohistochemistry; RFS, recurrence-free survival; OS, overall survival.
Received: July 20, 2016 Accepted: December 12, 2016 Published: January 02, 2017
The spondin-2 correlated with tumor progression in many malignancies. However, the role of spondin-2 in gastric cancer has not been thoroughly elucidated. Spondin-2 and matrix metallopeptidase 9 (MMP-9) expression was detected by immunohistochemistry in 174 gastric carcinoma tissues. The relationship between the expression of spondin-2 and MMP-9, clinicopathological/prognostic value in gastric cancer was examined. Spondin-2 was significantly higher in gastric cancer than that in adjacent non-tumorous tissues. Spondin-2 overexpression was significantly associated with well differentiation, depth of invasion, lymph node metastasis, and advanced TNM stages. The expression levels of spondin-2 were increasing in both prominent serosal invasion group and lymph node metastasis group. In addition, spondin-2 was positively correlated with MMP-9 among 174 gastric cancer samples. In univariate and multivariate analyses, spondin-2 was an independent prognostic factor for both recurrence-free survival (RFS) and overall survival (OS). Moreover, spondin-2 overexpression was associated with poor prognosis in patients with gastric cancer in different risk groups. In conclusion, Spondin-2 overexpression contributes to tumor aggressiveness and prognosis, and could be a promising target for prognostic prediction in gastric cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.